LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone781-221-2266
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$105.57 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/3/2019 (Estimated)
OptionableOptionable
LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions
What is LeMaitre Vascular's stock symbol?
LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."
How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?
LeMaitre Vascular announced a quarterly dividend on Monday, July 22nd. Investors of record on Wednesday, August 21st will be paid a dividend of $0.085 per share on Thursday, September 5th. This represents a $0.34 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Tuesday, August 20th. View LeMaitre Vascular's Dividend History.
How were LeMaitre Vascular's earnings last quarter?
LeMaitre Vascular Inc (NASDAQ:LMAT) issued its earnings results on Wednesday, July, 24th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.21 by $0.02. The medical instruments supplier earned $29.48 million during the quarter, compared to analyst estimates of $28.90 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 16.72%. LeMaitre Vascular's revenue was up 9.1% compared to the same quarter last year. During the same period last year, the firm earned $0.43 EPS. View LeMaitre Vascular's Earnings History.
When is LeMaitre Vascular's next earnings date?
What guidance has LeMaitre Vascular issued on next quarter's earnings?
LeMaitre Vascular issued an update on its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share (EPS) guidance of $0.84-0.88 for the period, compared to the Thomson Reuters consensus estimate of $0.83. The company issued revenue guidance of $115.5-116.7 million, compared to the consensus revenue estimate of $114.09 million.
What price target have analysts set for LMAT?
5 equities research analysts have issued 1-year price objectives for LeMaitre Vascular's stock. Their predictions range from $32.00 to $37.00. On average, they expect LeMaitre Vascular's stock price to reach $34.80 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for LeMaitre Vascular.
What is the consensus analysts' recommendation for LeMaitre Vascular?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for LeMaitre Vascular.
What are Wall Street analysts saying about LeMaitre Vascular stock?
Here are some recent quotes from research analysts about LeMaitre Vascular stock:
- 1. According to Zacks Investment Research, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (7/27/2019)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on LMAT shares and are increasing our price target to $32 (from $30 previously) given the encouraging organic growth (and particularly the strong unit volume growth). We think margins will expand meaningfully (vs. Q1) for the remainder of FY/19 and step up again in FY/20 as recently-hired sale reps become increasingly productive. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now." (5/2/2019)
Has LeMaitre Vascular been receiving favorable news coverage?
News stories about LMAT stock have trended negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. LeMaitre Vascular earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for LeMaitre Vascular.
Are investors shorting LeMaitre Vascular?
LeMaitre Vascular saw a increase in short interest in August. As of August 31st, there was short interest totalling 1,637,500 shares, an increase of 5.4% from the July 31st total of 1,553,300 shares. Based on an average daily volume of 101,700 shares, the days-to-cover ratio is currently 16.1 days. Currently, 10.2% of the company's stock are short sold. View LeMaitre Vascular's Current Options Chain.
Who are some of LeMaitre Vascular's key competitors?
Some companies that are related to LeMaitre Vascular include Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX) and Anika Therapeutics (ANIK).
What other stocks do shareholders of LeMaitre Vascular own?
Who are LeMaitre Vascular's key executives?
LeMaitre Vascular's management team includes the folowing people:
- Mr. George W. LeMaitre, Chairman & CEO (Age 54)
- Mr. David B. Roberts, Pres & Director (Age 55)
- Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 54)
- Mr. Trent G. Kamke, Sr. VP of Operations (Age 48)
- Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 85)
Who are LeMaitre Vascular's major shareholders?
LeMaitre Vascular's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.71%), Conestoga Capital Advisors LLC (8.85%), Vanguard Group Inc. (6.73%), Janus Henderson Group PLC (3.39%), Janus Henderson Group PLC (3.39%) and Copeland Capital Management LLC (1.97%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.
Which major investors are selling LeMaitre Vascular stock?
LMAT stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Wedge Capital Management L L P NC, Invesco Ltd., THB Asset Management, BlackRock Inc., Marshall Wace LLP, Dupont Capital Management Corp and AWM Investment Company Inc.. Company insiders that have sold LeMaitre Vascular company stock in the last year include George W Lemaitre, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.
Which major investors are buying LeMaitre Vascular stock?
LMAT stock was purchased by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, GW&K Investment Management LLC, Morgan Stanley, Nuveen Asset Management LLC, Amundi Pioneer Asset Management Inc., Russell Investments Group Ltd., Renaissance Technologies LLC and Conestoga Capital Advisors LLC. View Insider Buying and Selling for LeMaitre Vascular.
How do I buy shares of LeMaitre Vascular?
Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is LeMaitre Vascular's stock price today?
One share of LMAT stock can currently be purchased for approximately $35.20.
How big of a company is LeMaitre Vascular?
LeMaitre Vascular has a market capitalization of $698.61 million and generates $105.57 million in revenue each year. The medical instruments supplier earns $22.94 million in net income (profit) each year or $0.84 on an earnings per share basis. View Additional Information About LeMaitre Vascular.
What is LeMaitre Vascular's official website?
How can I contact LeMaitre Vascular?
LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.
MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)
MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
